NPS Pharmaceuticals Has Returned 24.7% Since SmarTrend Recommendation (NPSP)
Comtex SmarTrend(R) - Mon Dec 22, 9:16AM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 2 months, NPS Pharmaceuticals has returned 24.68% as of today's recent price of $35.03.
NPSP: 35.06 (+1.18)
NPS Pharmaceuticals and Shire Up on Takeover Rumors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 5:30PM CST
A report from Bloomberg indicated that the Shire is considering a potential acquisition of the NPS Pharma.
CBST: 100.29 (-0.09), MRK: 57.46 (+0.25), SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18), ABBV: 66.21 (+1.86)
Nasdaq stocks posting largest percentage increases
AP - Thu Dec 18, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CERS: 6.49 (+0.29), PTRY: 36.78 (+0.28), DRIV: 24.49 (+0.09), MTLS: 9.12 (-0.08), VOLC: 17.95 (+0.02), NPSP: 35.06 (+1.18), NYNY: 7.89 (+0.32), XNCR: 16.83 (+0.77), AREX: 6.98 (-0.11)
Market Driven by Key Factors: Complementary Research on General Mills, The Pantry, Approach Resources, NPS and Digital River
PR Newswire - Thu Dec 18, 8:14AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including General Mills (NYSE: GIS), The Pantry (NASDAQ: PTRY), Approach Resources (NASDAQ: AREX), NPS (NASDAQ: NPSP), and Digital River (NASDAQ: DRIV). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
DRIV: 24.49 (+0.09), PTRY: 36.78 (+0.28), NPSP: 35.06 (+1.18), GIS: 54.31 (-0.10), AREX: 6.98 (-0.11)
NPS Pharmaceuticals (NPSP) Jumps: Stock Moves 18.5% Up - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 7:51AM CST
NPS Pharmaceuticals, Inc. (NPSP) was a big mover last session, as its shares rose almost 19% on the day.
SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18)
After Yesterday's Rally of 18.48% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed Dec 17, 4:40PM CST
NPS Pharmaceuticals (NASDAQ:NPSP) traded in a range yesterday that spanned from a low of $30.26 to a high of $37.50. Yesterday, the shares gained 18.5%, which took the trading range above the 3-day high of $32.42 on volume of 5.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NPSP: 35.06 (+1.18)
Why NPS Pharmaceuticals, Inc. Stock Lifted Off in Midday Trading
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 17, 1:30PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NPS Pharmaceuticals , a biopharmaceutical...
SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18), ABBV: 66.21 (+1.86)
NPS Pharma up 20% on takeover buzz
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 10:21AM CST
SHPG: 209.29 (+0.07), NPSP: 35.06 (+1.18)
NPS Pharmaceuticals (NPSP) Marked As A Barbarian At The Gate
at The Street - Wed Dec 17, 10:01AM CST
Trade-Ideas LLC identified NPS Pharmaceuticals (NPSP) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
NPSP: 35.06 (+1.18)
Critical Alerts For Linn Energy, Delta Airlines, Herbalife, Ambarella and NPS Pharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Dec 17, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for LINE, DAL, HLF, AMBA and NPSP.
AMBA: 52.05 (+0.72), HLF: 37.98 (+0.20), DAL: 48.05 (+0.92), NPSP: 35.06 (+1.18), LINE: 10.93 (-0.32)
NPS Pharmaceuticals Shares Up 11.3% Since SmarTrend's Buy Recommendation (NPSP)
Comtex SmarTrend(R) - Fri Dec 12, 5:01PM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 2 months, NPS Pharmaceuticals has returned 11.34% as of today's recent price of $31.28.
NPSP: 35.06 (+1.18)
Secondary Hyperparathyroidism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x9vld/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/6x9vld/secondary
OPK: 9.63 (+0.21), NPSP: 35.06 (+1.18), AMGN: 160.67 (+3.15), NKTR: 15.02 (+0.23)
Wedbush Securities' David Nierengarten On Genetic Cures For Disease: Impossible Dream Come True?
Life Sciences Report - at Seeking Alpha - Thu Dec 11, 1:57PM CST
Clinicians like to speak in terms of "managing" disease. That term of art is an admission that, in most cases, they can't cure the serious problems confronting patients. In this interview with The Life Sciences Report , David Nierengarten of...
BLUE: 88.76 (+3.23), AGTC: 20.96 (+0.22), NPSP: 35.06 (+1.18)
18.7% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Fri Dec 05, 5:10PM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 2 months, NPS Pharmaceuticals has returned 18.70% as of today's recent price of $33.35.
NPSP: 35.06 (+1.18)
NPS Pharma to Present at Oppenheimer Healthcare Conference
Business Wire - Thu Dec 04, 7:10AM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference in New York on Thursday, December 11, 2014 at 9:45 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors' calendar of events page on the NPS Pharma website at http://ir.npsp.com/events.cfm.
NPSP: 35.06 (+1.18)
European Medicines Agency Validates Marketing Authorization Application for Natpar(R) (parathyroid hormone (rDNA)) in Hypoparathyroidism
Business Wire - Tue Dec 02, 8:16AM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases, today announced that the European Medicines Agency (EMA) has validated and initiated its review of the company's marketing authorization application (MAA) for Natpar(R) (parathyroid hormone (rDNA)) for the treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH). If approved, Natpar would be the first and only PTH replacement therapy in Europe for patients with Hypoparathyroidism.
NPSP: 35.06 (+1.18)
22.6% Return Seen to Date on SmarTrend NPS Pharmaceuticals Call (NPSP)
Comtex SmarTrend(R) - Fri Nov 28, 11:04AM CST
SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on October 20th, 2014 at $28.10. In approximately 1 month, NPS Pharmaceuticals has returned 22.62% as of today's recent price of $34.45.
NPSP: 35.06 (+1.18)
NPS Pharmaceuticals' SBS Drug Gets Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 3:45PM CST
NPS Pharmaceuticals (NPSP) announced that teduglutide has received orphan drug designation in Japan for the treatment of short bowel syndrome.
LCI: 42.29 (+1.79), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44), NPSP: 35.06 (+1.18)
NPS Pharma to Present at Deutsche Bank BioFEST Conference
Business Wire - Tue Nov 25, 3:10PM CST
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is scheduled to present at the 2014 Deutsche Bank BioFEST Conference in Boston on Tuesday, December 2, 2014 at 9:55 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors' calendar of events page on the NPS Pharma website at http://ir.npsp.com/events.cfm.
NPSP: 35.06 (+1.18), DB: 30.95 (+0.04)
Post Earnings Update: NPS Pharmaceuticals Has Climbed 18.9% Higher in Past 2 Weeks (NPSP)
Comtex SmarTrend(R) - Mon Nov 24, 9:23AM CST
14 days ago, on November 10th, 2014, NPS Pharmaceuticals (NASDAQ:NPSP) reported its earnings. Analysts, on average, expected earnings of $0.02 per share on sales of $59.8 million. NPS Pharmaceuticals actually reported a loss of $0.02 per share on sales of $57.2 million, missing EPS estimates by $0.04 and missing revenue estimates by $2.6 million. Shares of NPS Pharmaceuticals have climbed from $26.91 to $32.00, representing a gain of 18.9% since the company reported earnings 14 days ago.
NPSP: 35.06 (+1.18)